Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of $215.00. The company’s shares closed yesterday at $159.81.
Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Pfizer. According to TipRanks, Chen has an average return of -9.3% and a 39.68% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Johnson & Johnson also received a Buy from TD Cowen’s Josh Jennings in a report issued today. However, yesterday, Bank of America Securities maintained a Hold rating on Johnson & Johnson (NYSE: JNJ).
See the top stocks recommended by analysts >>
The company has a one-year high of $173.31 and a one-year low of $143.80. Currently, Johnson & Johnson has an average volume of 6.77M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson (JNJ) Company Description:
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
- Johnson & Johnson Earnings Report: Did it Beat Expectations?
- Johnson & Johnson (NYSE:JNJ) Drops despite Q4 Beat
- Options Volatility and Implied Earnings Moves Today, January 23, 2024
- Notable companies reporting before tomorrow’s open
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
